Internet-Based Lifestyle Intervention for Prostate Cancer Survivors
(iLIVE Trial)
Trial Summary
What is the purpose of this trial?
This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment iLIVE for prostate cancer survivors?
Research suggests that web-based lifestyle interventions, like iLIVE, can help prostate cancer survivors improve their physical activity and diet, which may enhance their quality of life and prognosis. These interventions are accessible and can be tailored to individual needs, making them a promising option for supporting healthier lifestyle habits.12345
Is the Internet-Based Lifestyle Intervention safe for prostate cancer survivors?
How is the iLIVE treatment different from other treatments for prostate cancer survivors?
The iLIVE treatment is unique because it is an internet-based lifestyle intervention specifically designed to help prostate cancer survivors improve their physical activity and dietary habits, which can enhance their quality of life and prognosis. Unlike traditional treatments, it leverages the internet to provide scalable and accessible support, making it easier for survivors to adopt healthier lifestyles.12569
Research Team
Kerri Winters-Stone
Principal Investigator
OHSU Knight Cancer Institute
Eligibility Criteria
This trial is for English-speaking men over 18 with prostate cancer who've had at least 6 months of ADT in the past decade, are obese but not morbidly so (BMI >30 to <50), show signs of frailty, and have internet access. They shouldn't be on a diet or exercise plan, have other active cancers except non-melanoma skin cancer, or any condition that affects weight/body composition like Cushing's syndrome.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants receive online access to an interactive weight loss website and participate in online group-based resistance training sessions (iLIVE). They also use a Fitbit fitness tracker and Aria smart scale.
Follow-up
Participants are monitored for changes in obesity, frailty, and other health outcomes after the intervention.
Treatment Details
Interventions
- iLIVE
iLIVE is already approved in United States for the following indications:
- Obesity and frailty in prostate cancer survivors
Find a Clinic Near You
Who Is Running the Clinical Trial?
OHSU Knight Cancer Institute
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Oregon Health and Science University
Collaborator
University of Alabama at Birmingham
Collaborator